Skip to main
ABVX

Abivax SA (ABVX) Stock Forecast & Price Target

Abivax SA (ABVX) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 58%
Hold 0%
Sell 8%
Strong Sell 0%

Bulls say

Abivax is an emerging biotech company with a strong management team that has shown potential in developing obefazimod for the treatment of ulcerative colitis and other IBDs. With a Buy rating and a target price of $140, the stock is expected to perform well due to the high unmet need for treatments in the IBD market and potential partnerships and acquisitions. Investors should closely monitor the progress of the Phase 2 trial and any updates on the drug's potential approval and market launch.

Bears say

Abivax is facing stiff competition in the market for inflammatory bowel disease treatments, with potential downsides in the case of failed acquisition or safety concerns. While the company has a strong management team and enough cash to continue operations for a certain period of time, concerns about the efficacy and potential for acquisition of its drug obefazimod may limit its success in the long term. Its potential in a growing market is also hindered by competition from biosimilars and new treatments, as well as the presence of other highly valued pharmaceutical and biotechnology companies in the market.

Abivax SA (ABVX) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 58% recommend Buy, 0% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abivax SA (ABVX) Forecast

Analysts have given Abivax SA (ABVX) a Buy based on their latest research and market trends.

According to 12 analysts, Abivax SA (ABVX) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $136.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $136.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abivax SA (ABVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.